• search
For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts

Changes in fat cells linked to diabetes

By Samyuktha
|

Washington, July 7 (ANI): A new research from the University of Cincinnati (UC) suggests that cellular changes in fat tissue-not the immune system-lead to the 'hyperinflammation' characteristic of obesity-related glucose intolerance and type 2 diabetes.

Cancer and cell biology experts say this new discovery about the cellular mechanisms behind glucose intolerance may provide a different target for drugs to treat type 2 diabetes as well as insights into how aggressive cancers form.

For this study, lead author Jorge Moscat and his UC collaborator Maria Diaz-Meco, looked at the role of a specific gene known as protein kinase C (PKC)-zeta, which has been implicated as a key cellular contributor to malignant tumor growth.

Using a preclinical animal model, they found that PKC-zeta had a dual role in the molecular signaling that leads to inflammation, switching from acting as a regulator of inflammation to a proinflammation agent in different circumstances.

"This finding is quite novel because current drug development efforts target immune cells (macrophages, T-cells) to eliminate this hyperinflammation. Our research suggests obesity-related glucose intolerance has nothing to do with the immune system. It may be more effective to target adipocytes (fat cells)," said Moscat.

In normal cells, explains Moscat, PKC-zeta regulates the balance between cellular inflammatory responses to maintain glucose control. During obesity-induced inflammation, however, the function of PKC-zeta changes and the molecule begins to promote inflammation by causing adipocytes to secrete a substance (IL-6) that travels in large quantities to the liver to cause insulin resistance.

"We believe a similar mechanism of action is at play in malignant tumor development. Now we are trying to understand how PKC-zeta regulates IL6 to better determine how we can manipulate the protein to help prevent diabetes and cancer," he added.

Moscat and his team are working with investigators at UC's Drug Discovery Center to screen compounds that will inhibit PKC-zeta to be used in further research.

The study is reported in the July 7, 2010, issue of the scientific journal Cell Metabolism. (ANI)

For Daily Alerts
Get Instant News Updates
Enable
x
Notification Settings X
Time Settings
Done
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more